In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2.

Remdesivir (RDV), a broadly acting nucleoside analogue, is the only FDA approved small molecule antiviral for the treatment of COVID-19 patients. To date, there are no reports identifying SARS-CoV-2 RDV resistance in patients, animal models or in vitro. Here, we selected drug-resistant viral populat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Agnieszka M Szemiel, Andres Merits, Richard J Orton, Oscar A MacLean, Rute Maria Pinto, Arthur Wickenhagen, Gauthier Lieber, Matthew L Turnbull, Sainan Wang, Wilhelm Furnon, Nicolas M Suarez, Daniel Mair, Ana da Silva Filipe, Brian J Willett, Sam J Wilson, Arvind H Patel, Emma C Thomson, Massimo Palmarini, Alain Kohl, Meredith E Stewart
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Immunologic diseases. Allergy
RC581-607
Biology (General)
QH301-705.5
Acceso en línea:https://doaj.org/article/7d89e76f634d4950a6f0243895093b37
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares